Elmussareh Muhammad, Young Matthew, Ordell Sundelin Maria, Bak-Ipsen Camilla Brinkmann, Graumann Ole, Jensen Jørgen Bjerggaard
a Department of Urology , Mid Yorkshire Hospitals NHS Trust , Wakefield , UK.
b Department of Urology , Aarhus University Hospital , Aarhus , Denmark.
Scand J Urol. 2017 Aug;51(4):282-289. doi: 10.1080/21681805.2017.1310759. Epub 2017 Apr 13.
The aim of this study was to review haematuria referrals to a large university hospital in Denmark, based on the previous Danish guidelines for haematuria referral (before January 2016), to evaluate the pattern of referrals and the cancer detection rates and compare these with the current guidelines.
A retrospective study was undertaken of all patients referred from primary care for the evaluation of haematuria from January 2013 to December 2014. All patients underwent cystoscopic examination and upper urinary tract evaluation using computed tomography. Patients' demographics, type of haematuria, presence of urinary symptoms and cancer detection rates were recorded.
The study included 1577 patients, with a mean age of 63 years (range 16-96 years). Of these, 56.4% had visible haematuria (VH) and 43.6% were referred for non-visible haematuria (NVH). In total, 228 malignancies were detected (14.5% cancer detection rate). Overall, 11.2% of patients had bladder cancer, 1.8% renal cancer and 0.4% upper tract transitional cell carcinoma. In the VH group, 205 malignancies were detected (23% cancer detection rate). The detection rate was higher for those with asymptomatic VH (24.6%) than for those with symptomatic VH (15.4%). The cancer detection rate for symptomatic NVH was 9.1%, with only three cancers diagnosed in those younger than 60 years of age. For asymptomatic NVH, the cancer detection rate was only 1.5%, with a total of eight urological malignancies diagnosed in patients aged 60 years or older.
The new Danish referral pathway has an acceptable capture rate for patients presenting with haematuria of all severities. The overall cancer detection rate of 14.5%, and 23% for patients with VH in this study, is an important validation of previous studies. A cancer detection rate of greater than 30% was shown in patients with VH over 70 years old.
本研究旨在根据丹麦之前的血尿转诊指南(2016年1月之前),回顾转诊至丹麦一家大型大学医院的血尿患者情况,评估转诊模式和癌症检出率,并与当前指南进行比较。
对2013年1月至2014年12月从初级保健机构转诊来评估血尿的所有患者进行回顾性研究。所有患者均接受了膀胱镜检查和使用计算机断层扫描的上尿路评估。记录患者的人口统计学资料、血尿类型、泌尿系统症状的存在情况以及癌症检出率。
该研究纳入了1577例患者,平均年龄63岁(范围16 - 96岁)。其中,56.4%为肉眼血尿(VH),43.6%为镜下血尿(NVH)。共检测到228例恶性肿瘤(癌症检出率为14.5%)。总体而言,11.2%的患者患有膀胱癌,1.8%患有肾癌,0.4%患有上尿路移行细胞癌。在VH组中,检测到205例恶性肿瘤(癌症检出率为23%)。无症状VH患者的检出率(24.6%)高于有症状VH患者(15.4%)。有症状NVH的癌症检出率为9.1%,60岁以下患者仅诊断出3例癌症。对于无症状NVH,癌症检出率仅为1.5%,60岁及以上患者共诊断出8例泌尿系统恶性肿瘤。
丹麦新的转诊途径对所有严重程度血尿患者的捕获率是可接受的。本研究中总体癌症检出率为14.5%,VH患者为23%,这是对先前研究的重要验证。70岁以上VH患者的癌症检出率超过30%。